Table of Contents
CsA Elimination Studies
Study 310 Recipient Demographics
Study 310 Equivalent 12 Month Graft Survival*
Study 310 Equivalent 12 Month Patient Survival
Study 310: Similar Incidence of First Biopsy–Confirmed Acute Rejection*
Low Incidence of Acute Rejection at 3 Months
Low Incidence of Acute Rejection at 12 Months
Study 310: Outcome in Rejectors Following Randomization (Months 3 to 12)
Study 310: No Difference in Histologic Grade of First Biopsy-Confirmed Acute Rejection*
Study 310: Adverse Impact of Acute Rejection Lessened with CsA Elimination*
Study 310: Summary of the Clinical Impact of Acute Rejection
Study 310: Similar Rates of Efficacy Failure at 12 Months
Study 310: Similar Incidence of Treatment Failure (%) at ? Month 15
Study 310: Improved Renal Function in the Intent-to-Treat Population at Month 12*
Study 310: Improved Renal Function Following CsA Elimination**
Study 310: Quartile Analysis: Improved Renal Function at 12 Months*
Summary of Efficacy Data for Study 310
Study 212 Recipient Demographic Characteristics
Study 212 Similar 12 Month Graft Survival
Study 212 Similar 12 Month Patient Survival*
Study 212: Similar Incidence of First Biopsy–Confirmed Acute Rejection*
Study 212: Outcome in Rejectors Following CsA Withdrawal (Months 2 to 12)
Study 212: Histologic Grade of First Biopsy-Confirmed Acute Rejection (Months 2 to 12)
PPT Slide
Study 212: Improved Nankivell GFR Following CsA Elimination (Intent-to-Treat Analysis)
Study 212: Improved Renal Function Following CsA Elimination*
Study 212: Improved Measured GFR Following CsA Elimination*
Study 212: Improved Renal Function Following CsA Elimination*
Study 212: Quartile Analysis: Improved Renal Function at 12 Months*
Summary of Clinical Studies
|